Our AAV-based BCD gene transfer therapy, recombinant AAV vector encoding human CYP4V2 protein (AAV.CYP4V2), reduced RPE cell death in BCD patients’ iPS-RPE cell lines in preclinical POC study. Here, CYP4V2 is linked to Bietti crystalline dystrophy.